Akebia Therapeutics Inc.
AKBA
Market Cap$226.36M
Close$
$2.57
129.6% upside
Current Fair Value
129.6% upsideUndervalued by 129.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $226.36 Million |
|---|---|
| Enterprise Value | $222.18 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.23 |
| Beta | 1.32 |
| Outstanding Shares | 209,596,378 |
| Avg 30 Day Volume | 2,947,315 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.18 |
|---|---|
| PEG | 16.5 |
| Price to Sales | - |
| Price to Book Ratio | -1.12 |
| Enterprise Value to Revenue | 1.19 |
| Enterprise Value to EBIT | -6.15 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | -1.39 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler